VEGFA and neoplasm: Bevacizumab suppresses tumor blood vessel growth by binding vascular endothelial growth factor (VEGF) in blood, and was approved for second line treatment of recurrent glioblastoma multiforme (GBM) in 2009 (Han et al, 2014).